Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Øivind Foss

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
European Journal of Applied Physiology|October 27, 2004
Cadence and performance in elite cyclistsØivind Foss, Jostein Hallén
European Journal of Applied Physiology|July 3, 2004
The most economical cadence increases with increasing workloadØivind Foss, Jostein Hallén
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2025
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 studyPaul Lorigan, Theresa Michelle Medina, Marta Nyakas, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
European Journal of Applied Physiology|October 27, 2004
Cadence and performance in elite cyclistsØivind Foss, Jostein Hallén
European Journal of Applied Physiology|July 3, 2004
The most economical cadence increases with increasing workloadØivind Foss, Jostein Hallén
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2025
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 studyPaul Lorigan, Theresa Michelle Medina, Marta Nyakas, et al.
Pageof 1